LIMN Liminatus Pharma, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1971387 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,098.0%
TTM EPS YoY-860.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-471.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets91.2%
Debt / equity0.00x
Current ratio1.12x
Interest coverage-53.78x
Cash quality & payout
Operating cash flow / net income0.32x
Accruals ratio-321.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $600,000 | $400,000 | — | — | — | — | $0 | $357,066 |
| SG&A expense | $778,908 | $700,898 | $884,211 | $701,170 | $1.12M | $264,220 | $167,077 | $186,081 |
| Operating income | -$1.38M | -$1.10M | -$884,211 | -$701,170 | -$1.12M | -$264,220 | -$167,077 | -$543,147 |
| Interest expense | $18,844 | $18,638 | $19,051 | $19,052 | $62,288 | $115,512 | $106,164 | $92,706 |
| Net income | -$1.41M | -$1.12M | -$8.17M | -$1.82M | $113,287 | -$327,526 | -$229,752 | -$601,372 |
| EBITDA | -$1.38M | -$1.10M | -$883,668 | -$700,628 | — | — | — | — |
| EPS (basic) | -0.03 | -0.03 | — | -0.07 | 0.00 | -0.02 | — | -0.03 |
| EPS (diluted) | -0.03 | -0.03 | — | -0.07 | 0.00 | -0.02 | — | -0.03 |
| Weighted avg. shares (diluted) | 48.40M | 36.00M | — | 27.01M | 23.30M | 17.50M | — | 17.50M |
| Balance sheet | ||||||||
| Cash & equivalents | $3.02M | $1.91M | $337,655 | $724,502 | $1.34M | $0 | $56,319 | — |
| Current assets | $3.39M | $2.78M | $500,574 | $1.20M | $1.78M | — | $5.28M | — |
| PP&E, net | $11,235 | $11,703 | $12,221 | $12,764 | $198 | — | $941 | — |
| Total assets | $3.40M | $2.79M | $512,795 | $1.34M | $1.91M | — | $5.41M | — |
| Current liabilities | $3.04M | $2.89M | $10.30M | $2.86M | $10.52M | — | $24.75M | — |
| Short-term debt | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | — | $19.97M | — |
| Total liabilities | $3.10M | $2.92M | $10.33M | $2.99M | $10.72M | $1,060 | $24.75M | — |
| Shareholders' equity | $300,612 | -$132,596 | -$9.81M | -$1.65M | -$8.81M | -$19.67M | -$19.34M | -$19.11M |
| Shares outstanding | 55.97M | 44.88M | 27.06M | 27.06M | 26.01M | — | 17.50M | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$969,999 | -$2.02M | -$386,847 | -$600,612 | -$8.98M | -$159,393 | -$140,660 | -$206,119 |
| Capital expenditure | — | — | $0 | — | — | — | — | — |
| Free cash flow | — | — | -$386,847 | — | — | — | — | — |
| Investing cash flow | — | — | $0 | -$13,108 | -$200,000 | -$575,000 | -$550,000 | -$800,000 |
| Financing cash flow | $2.08M | $3.59M | $0 | $0 | $10.32M | $713,000 | $700,000 | $1.02M |
| Depreciation & amortization | $468 | $518 | $543 | $542 | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.